4:30
Measurable residual disease in AML
Alan Burnett
2:45
Predicting long-term outcomes in myeloma: MRD
Philip McCarthy
2:16
MRD: making clinical decisions in ALL
Stephan Grupp
2:34
MRD is the best predictor for treatment success in AML
Fabio Guolo
1:39
Using MRD to inform allocation of stem cell transplants in ALL and AML
Fabio Guolo
2:29
Detecting MRD at finer scales in CLL
Florence Cymbalista
1:56
MRD: common misconceptions and clinical considerations
Fabio Guolo
2:11
NGS vs. flow cytometry for MRD in MM
Bruno Paiva
2:05
MRD in AML clinical practice
Fabio Guolo
2:22
Next-generation methodologies: the future for MRD monitoring in ALL?
Wendy Stock
1:17
Developments for the use of MRD in AML
Christopher Hourigan
1:06
Measuring MRD in AML: current landscape and future outlook
Christopher Hourigan
1:25
MRD testing will be a part of future AML clinical trials
Christopher Hourigan
2:18
New applications for MRD measurement in myeloma: MRD ‘over time’
Ola Landgren
2:57
When is the optimal time to measure minimal residual disease (MRD) in myeloma patients?
Ola Landgren
3:28
Bringing minimal residual disease (MRD) measurement to the clinic
Ola Landgren
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals